A Multiple Ascending Dose Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intrathecally Administered LY4256984 in Participants With Sporadic Amyotrophic Lateral Sclerosis
A Multiple Ascending Dose Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intrathecally Administered LY4256984 in Participants With Sporadic Amyotrophic Lateral Sclerosis
The purpose of this study is to evaluate how well LY4256984 is tolerated and what side effects may occur in participants with sporadic amyotrophic lateral sclerosis (ALS). The study drug will be administered intrathecally (IT) into the spine. Blood tests will be performed to check how much LY4256984 gets into the bloodstream and how long it takes the body to eliminate it.
Inclusion Criteria:
Exclusion Criteria:
LillyTrials@Lilly.com1-317-615-4559
clinical_inquiry_hub@lilly.com
Leuven, 3000, Belgium
(321) 634-4280
Rostock, 18147, Germany
403-210-7006
780.248.1089
519-663-3597
514-449-8741
4134806860
4936419323426
49 (0)381 494-9541
(497315) 006-3099
31887553204
+34 933359011 ext 8486
34644490025